TMCnet News
Antares Pharma Adds New VP(Wireless News Via Thomson Dialog NewsEdge) Antares Pharma announced that Kaushik J. Dave, PhD, RPh, MBA, has joined the company as Vice President of Clinical and Regulatory Affairs. Dr. Dave has over 15 years of experience in the pharmaceutical industry with both large and specialty pharma companies, directing product development from preclinical to clinical through to commercialization. His broad experience includes securing multiple product approvals from the U. S. Food and Drug Administration (FDA), European Medicines Agency (EMEA) and the Medicines Control Agency (MCA). Prior to joining Antares Pharma, Dr. Dave was employed by drug delivery companies Transave and Palatin Technologies, as well as pharmaceutical companies Schering Plough and Merck, where he was responsible for IND and NDA submissions for more than 20 products. He obtained his Pharmacy degree from University of Bath, UK, a PhD in pharmaceutical chemistry from the University of Kansas, and an MBA from the Wharton School. "We are very pleased to have Dr. Dave join our management team at this juncture; he brings a wealth of clinical and regulatory expertise to lead our clinical development program. Presently we are enrolling patients in our pivotal trials for Anturol ATD (Advanced Transdermal Gel Delivery System) for the treatment of overactive bladder. We are also initiating a clinical program for our proprietary CNS (ATD gel) product, AP-1126. Additionally, we are planning a Phase II trial with the Population Council for our Nestorone/estradiol ATD gel contraceptive, to commence later this year. The progress of our clinical program demonstrates our advancement toward becoming a principal specialty pharma company," said Jack E. Stover, President and CEO. Antares Pharma is a specialized pharma product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has three validated drug delivery platforms: the ATDTM Advanced Transdermal Delivery system, subcutaneous injection technology platforms including both VibexTM disposable mini-needle injection device and ValeoTM/Vision reusable needle-free injection devices; and Easy TecTM oral fast-melt technology. ((Comments on this story may be sent to [email protected])) ((Distributed on behalf of 10Meters via M2 Communications Ltd - http://www.m2.com)) ((10Meters - http://www.10meters.com)) Copyright ? 2008 Wireless News |